{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+2+of+Aluminum+Adjuvant", "query": { "intervention": "Dose 2 of Aluminum Adjuvant" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 40, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+2+of+Aluminum+Adjuvant&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-01T02:49:35.812Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02963909", "title": "A Phase 1, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated Vaccine (ZPIV) With Alum Adjuvant in Healthy Flavivirus-naive and Flavivirus-Primed Subjects.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Zika Virus Infection" ], "interventions": [ { "name": "IXIARO", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" }, { "name": "YF Vax 17D Strain", "type": "BIOLOGICAL" }, { "name": "Zika Virus Purified Inactivated Vaccine (ZPIV)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "ALL", "summary": "18 Years to 49 Years" }, "enrollment_count": 75, "start_date": "2016-11-01", "completion_date": "2018-10-30", "has_results": false, "last_update_posted_date": "2024-04-22", "last_synced_at": "2026-10-01T02:49:35.812Z", "location_count": 1, "location_summary": "Silver Spring, Maryland", "locations": [ { "city": "Silver Spring", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02963909" }, { "nct_id": "NCT03480802", "title": "A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pneumococcal Infections" ], "interventions": [ { "name": "V114", "type": "BIOLOGICAL" }, { "name": "Prevnar 13™", "type": "BIOLOGICAL" }, { "name": "PNEUMOVAX™23", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 302, "start_date": "2018-07-06", "completion_date": "2020-01-17", "has_results": true, "last_update_posted_date": "2022-05-05", "last_synced_at": "2026-10-01T02:49:35.812Z", "location_count": 4, "location_summary": "Orlando, Florida • West Palm Beach, Florida • Houston, Texas", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" }, { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03480802" }, { "nct_id": "NCT01995617", "title": "Safety and Immunogenicity Study of Prophylactic Streptococcus Pneumoniae Vaccine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Streptococcus Pneumoniae" ], "interventions": [ { "name": "Placebo", "type": "BIOLOGICAL" }, { "name": "GEN-004 Low Dose", "type": "BIOLOGICAL" }, { "name": "GEN-004 Low Dose + Adjuvant", "type": "BIOLOGICAL" }, { "name": "GEN-004 Mid Dose", "type": "BIOLOGICAL" }, { "name": "GEN-004 Mid Dose + Adjuvant", "type": "BIOLOGICAL" }, { "name": "GEN-004 High Dose", "type": "BIOLOGICAL" }, { "name": "GEN-004 High Dose + Adjuvant", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Genocea Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 90, "start_date": "2013-11", "completion_date": "2015-02", "has_results": false, "last_update_posted_date": "2015-12-11", "last_synced_at": "2026-10-01T02:49:35.812Z", "location_count": 1, "location_summary": "Saint Paul, Minnesota", "locations": [ { "city": "Saint Paul", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01995617" }, { "nct_id": "NCT00382980", "title": "Dose-Escalating Trial Using Vero Cell-culture Derived H5N1 +/- Aluminum in Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Influenza" ], "interventions": [ { "name": "Aluminum hydroxide", "type": "BIOLOGICAL" }, { "name": "Inactivated Vero cell based whole virus influenza A/H5N1", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "18 Years to 40 Years" }, "enrollment_count": 308, "start_date": "2006-10", "completion_date": "2007-09", "has_results": false, "last_update_posted_date": "2010-08-27", "last_synced_at": "2026-10-01T02:49:35.812Z", "location_count": 5, "location_summary": "Stanford, California • Torrance, California • Baltimore, Maryland + 2 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00382980" }, { "nct_id": "NCT02304185", "title": "Safety, Tolerability and Immunogenicity Study of 2 Dose Levels of Trimeric Glycoprotein140 (gp140) in Healthy Adult Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "gp140, 50 mcg", "type": "BIOLOGICAL" }, { "name": "gp140, 50 mcg + Adjuvant", "type": "BIOLOGICAL" }, { "name": "gp140, 250 mcg", "type": "BIOLOGICAL" }, { "name": "gp140, 250 mcg + Adjuvant", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Crucell Holland BV", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 50, "start_date": "2014-12", "completion_date": "2016-04", "has_results": false, "last_update_posted_date": "2016-06-06", "last_synced_at": "2026-10-01T02:49:35.812Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02304185" }, { "nct_id": "NCT06799494", "title": "HPV Vaccine Reduced Dose", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HPV" ], "interventions": [ { "name": "Gardasil-9", "type": "BIOLOGICAL" }, { "name": "Lidocaine injection", "type": "DRUG" }, { "name": "Lorazepam", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 100, "start_date": "2025-08-06", "completion_date": "2028-09", "has_results": false, "last_update_posted_date": "2026-08-31", "last_synced_at": "2026-10-01T02:49:35.812Z", "location_count": 1, "location_summary": "Decatur, Georgia", "locations": [ { "city": "Decatur", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06799494" }, { "nct_id": "NCT03049488", "title": "Dose, Safety, Tolerability and Immunogenicity of a Stabilized Prefusion RSV F Subunit Protein Vaccine, VRC-RSVRGP084-00-VP (DS-Cav1), Alone or With Alum Adjuvant, in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Respiratory Syncytial Virus" ], "interventions": [ { "name": "VRC-RSVRGP084-00-VP", "type": "BIOLOGICAL" }, { "name": "Aluminum Hydroxide Suspension", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 95, "start_date": "2017-02-22", "completion_date": "2019-10-03", "has_results": true, "last_update_posted_date": "2020-10-23", "last_synced_at": "2026-10-01T02:49:35.812Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03049488" }, { "nct_id": "NCT00296634", "title": "H5 Vaccine Alone or With Adjuvant in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Influenza" ], "interventions": [ { "name": "Aluminum hydroxide", "type": "DRUG" }, { "name": "Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur pre-adsorbed)", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "ALL", "summary": "18 Years to 49 Years" }, "enrollment_count": 600, "start_date": "2006-03", "completion_date": "2006-12", "has_results": false, "last_update_posted_date": "2010-08-27", "last_synced_at": "2026-10-01T02:49:35.812Z", "location_count": 4, "location_summary": "Baltimore, Maryland • Rochester, New York • Durham, North Carolina + 1 more", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Rochester", "state": "New York" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00296634" }, { "nct_id": "NCT04456504", "title": "HepB-CpG Series for Healthcare Workers Who Are Hepatitis B Vaccine Nonresponders", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Healthcare Worker, Hepatitis B Vaccine, Nonresponder" ], "interventions": [ { "name": "Recombinant hepatitis B vaccine with CpG adjuvant", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "University of Wisconsin, Madison", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2020-09-15", "completion_date": "2023-12-06", "has_results": true, "last_update_posted_date": "2024-07-16", "last_synced_at": "2026-10-01T02:49:35.812Z", "location_count": 1, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT04456504" }, { "nct_id": "NCT05901636", "title": "A Clinical Study to Evaluate an Experimental Universal Influenza Vaccine, INFLUENZA G1 mHA, in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Influenza Prevention" ], "interventions": [ { "name": "INFLUENZA G1 mHA", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" }, { "name": "Al(OH)3", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Janssen Vaccines & Prevention B.V.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 170, "start_date": "2023-05-17", "completion_date": "2024-08-19", "has_results": true, "last_update_posted_date": "2025-09-08", "last_synced_at": "2026-10-01T02:49:35.812Z", "location_count": 4, "location_summary": "Miami Lakes, Florida • Lenexa, Kansas • Metairie, Louisiana + 1 more", "locations": [ { "city": "Miami Lakes", "state": "Florida" }, { "city": "Lenexa", "state": "Kansas" }, { "city": "Metairie", "state": "Louisiana" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05901636" } ] }